Yukichi Tanaka

Dr. Yukichi Tanaka


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Antioxidants
Verified
Journal Article
Open access
PDF file
NNNoriyuki Nagahara
Noriyuki Nagahara
MTMio Tanaka
Mio Tanaka
YTYukichi Tanaka
Yukichi Tanaka
TITakaaki Ito
Takaaki Ito
The antioxidant enzyme, 3-mercaptopyruvate sulfurtransferase (MST, EC 2.8.1.2) is localized in the cytosol and mitochondria, while the evolutionarily-related enzyme, rhodanese (thiosulfate sulfurtransferase, TST, EC 2.8.1.1) is localized in the mitochondria. Recently, both enzymes have been shown to produce hydrogen sulfide and polysulfide. Subcellular fractionation of liver mitochondria revealed that the TST activity ratio of MST-knockout (KO)/wild-type mice was approximately 2.5; MST activity was detected only in wild-type mice, as expected. The ratio of TST mRNA expression of KO/wild-type mice, as measured by real-time quantitative polymerase chain reaction analysis, was approximately 3.3. It is concluded that TST is overexpressed in MST-KO mice.

18 October 2013 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YTYukichi Tanaka
Yukichi Tanaka
TITakeshi Inoue
Takeshi Inoue
HHHiroshi Horie
Hiroshi Horie

1 April 2013 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
MYMariko Yoshida
Mariko Yoshida
KMKentaro Matsuoka
Kentaro Matsuoka
ANAtsuko Nakazawa
Atsuko Nakazawa
TITakeshi Inoue
Takeshi Inoue
HKHiroshi Kishimoto
Hiroshi Kishimoto
YTYukichi Tanaka
Yukichi Tanaka

11 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ATAngela Trobaugh-lotrario
Angela Trobaugh-lotrario
RMRudolf Maibach
Rudolf Maibach
DADaniel C. Aronson
Daniel C. Aronson
ARArun A Rangaswami
Arun A Rangaswami
BHBeate Häberle
Beate Häberle
DLDolores H. Lòpez-Terrada
Dolores H. Lòpez-Terrada
Small cell undifferentiated (SCU) histology and alpha-fetoprotein (AFP) levels below 100 ng/mL have been reported as poor prognostic factors in hepatoblastoma (HB); subsequent studies reported SMARCB1 mutations in some SCU HBs confirming the diagnosis of rhabdoid tumor. The Children’s Hepatic tumors International Collaboration (CHIC) database was queried for patients with HB who had AFP levels less than 100 ng/mL at diagnosis or were historically diagnosed as SCU HBs. Seventy-three of 1605 patients in the CHIC database were originally identified as SCU HB, HB with SCU component, or HB with low AFP levels. Upon retrospective review, they were re-classified as rhabdoid tumors (n = 11), HB with SCU component (n = 41), and HB with low AFP (n = 14). Seven were excluded for erroneously low AFP levels. Overall survival was 0% for patients with rhabdoid tumors, 76% for patients with HB with SCU component, and 64% for patients with HB with AFP less than 100 ng/mL. Patients with HB with SCU component or low AFP should be assessed for SMARCB1 mutations and, if confirmed, treated as rhabdoid tumors. When rhabdoid tumors are excluded, the presence of SCU component and low AFP at diagnosis were not associated with poor prognosis in patients diagnosed with HB.


30 September 2016 in Human Pathology
Verified
Journal Article
Closed access
MYMisa Yoshida
Misa Yoshida
SHSatoshi Hamanoue
Satoshi Hamanoue
MSMasafumi Seki
Masafumi Seki
MTMio Tanaka
Mio Tanaka
KYKenichi Yoshida
Kenichi Yoshida
YTYukichi Tanaka
Yukichi Tanaka